(40 days)
Glucose Meter-Check Solution for Infopia is intended for use to verify the performance and correct operation of Infopia blood glucose monitoring test systems utilizing Infopia glucose test strips. Glucose Meter-Check Solution for Infopia is intended for use by healthcare professionals and people with diabetes mellitus at home.
For In Vitro Diagnostic Use
Glucose Meter-Check Solution for Infopia is a buffered aqueous solution with glucose containing no ingredients of biological origin, or in concentrations qualifying as a controlled product under the Controlled Products Regulation. The Glucose Meter-Check Solution is formulated for optimal performance on Infopia glucose meters using Infopia test strips.
This material consists of viscosity-adjusted, aqueous glucose control solution prepared with a single concentration of D-glucose with recovery on the test systems in the range corresponding to Interval 2 of the glucose contration intervals for evalution of intermediate precision in ISO 151972 (96 to 144 mg/dL). This solution has been optimized to simulate the response of whole blood on the blood glucose test systems manufactured by Infopia using Infopia blood glucose test strips. The solution contains no hazardous, human or animal derived components.
Here's an analysis of the provided text regarding the acceptance criteria and study for the Glucose Meter-Check Solution for Infopia:
The submission K113764 is for a control solution, not an AI device, and therefore the majority of the requested information regarding AI device evaluation (such as sample sizes for test/training sets, expert ground truth, MRMC studies, standalone performance, etc.) is not applicable to this document. This document describes the equivalence of a new control solution to an existing one.
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria for a control solution are typically defined as its ability to produce glucose readings within a specified target range when tested with the intended blood glucose monitoring system. The predicate device's established target range serves as the basis for substantial equivalence.
| Acceptance Criteria (Predicate Device Target Range) | Reported Device Performance (New Device Target Range) |
|---|---|
| 94 – 140 mg/dL | 88 – 132 mg/dL |
Note: The new device's target range (88 – 132 mg/dL) falls within the established performance window for glucose concentration intervals for evaluation of intermediate precision in ISO 15197 (96 to 144 mg/dL), and is deemed substantially equivalent to the predicate.
2. Sample Size Used for the Test Set and Data Provenance
This information is not applicable as this is a medical device submission for a control solution, and not an AI device undergoing a performance study with a test set of data. The "tests conducted" section lists stability and response tests, but does not detail sample sizes as would be relevant for an AI model's test set.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications
This information is not applicable. Ground truth, in the context of an AI device, refers to expertly curated data for model comparison. For a control solution, the "truth" is its certified glucose concentration, which is established through analytical chemistry, not expert consensus on diagnostic images or clinical outcomes.
4. Adjudication Method for the Test Set
This information is not applicable. Adjudication methods are relevant for resolving discrepancies in expert interpretations, which is not pertinent to the evaluation of a glucose control solution.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
This information is not applicable. MRMC studies are used to evaluate the impact of AI on human reader performance, which doesn't apply to a control solution.
6. If a Standalone Performance (Algorithm Only Without Human-in-the-Loop) Was Done
This information is not applicable. There is no algorithm or AI component in this control solution.
7. The Type of Ground Truth Used
For the Glucose Meter-Check Solution, the "ground truth" implicitly refers to the analytical concentration of D-glucose in the buffered aqueous solution, established through chemical manufacturing and quality control processes. This is confirmed by the statement: "Glucose Meter-Check Solution for Infopia is a buffered aqueous solution with glucose..." and its formulation "with a single concentration of D-glucose".
8. The Sample Size for the Training Set
This information is not applicable, as there is no AI model or training set associated with this control solution.
9. How the Ground Truth for the Training Set Was Established
This information is not applicable, as there is no AI model or training set associated with this control solution.
Summary of the Study that Proves the Device Meets Acceptance Criteria:
The study proving the device meets acceptance criteria for this control solution primarily focuses on non-clinical tests comparing its characteristics and performance to a legally marketed predicate device (Infopia Control Solution K0572369).
The key aspects of the study demonstrating substantial equivalence include:
- Comparison of Technological Characteristics: A direct comparison table is provided, showing the new device shares fundamental characteristics with the predicate, such as:
- Name (Infopia Control Solution vs. Glucose Meter-Check Control Solution for Infopia)
- Number of levels (1, typical fasting glucose)
- Analytes (glucose)
- Container (6 mL LDPE vial with dispensing tip and cap)
- Fill volume (4 mL)
- Color (red)
- Matrix (Buffered, aqueous solution of D-Glucose, viscosity modifier, preservatives and other, non-reactive ingredients)
- Target Ranges: The new device's target range (88 – 132 mg/dL) was established and deemed acceptable when compared to the predicate's range (94 – 140 mg/dL). This range is also stated to correspond to Interval 2 of the glucose concentration intervals for the evaluation of intermediate precision in ISO 15197 (96 to 144 mg/dL), implying it meets recognized standards for control solution performance.
- Non-Clinical Performance Tests: The submission states that tests were conducted to verify specific performance requirements:
- Closed bottle stability (Shelf-life)
- Stability after opening (Use-life)
- Transport Stability
- Test response (This implicitly confirms that the solution provides readings within its specified range on the target glucose meters).
Conclusion drawn from these tests: "Comparison of technological characteristics, formulation and intended use to predicate devices listed in this summary support the claim of substantial equivalence." This means the new Glucose Meter-Check Solution for Infopia performs comparably to the predicate control solution, within acceptable parameters, ensuring it can effectively verify the performance of Infopia blood glucose monitoring test systems as intended.
{0}------------------------------------------------
JAN 3 0 2012
510(k) Summary1
Quality Solu
(a) (1) Submitter's name, address Bionostics, Inc. 7 Jackson Road Devens, MA 01434
Contact Person Randy Byrd VP, Chief Technical Officer (978) 772-7070 x 272
Date of preparation of this summary: 20 December 2011
- (2) Device trade or proprietary name: Glucose Meter-Check Solution for Infopia
Device common or usual name or classification name:
Single (Specified) Analyte Control, All Types, Assayed and Unassayed אור
| a prove and a program a comments of the many of the summerREGULATION MEDICALOFFIAITYAnd In Canada State 2 | and and the former of the many of the status and and any the moreREGULATION"NUMBER | 2000 - 10 15 15 - 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 | OFGUIA ISCRIPTION11.07 |
|---|---|---|---|
| Chemistry | A /1660 | Glucose Control |
l. Substantial Equivalence
Glucose Meter-Check Control Solution for Infopia is substantially equivalent in function, safety and efficacy to currently marketed devices for the same intended use as shown in the following tables:
| Characteristic | Predicate Device | Modified Device |
|---|---|---|
| Name: | Infopia Control Solution | Glucose Meter-Check ControlSolution for Infopia |
| 510(k), Date: | K0572369, Mar 21 2008 | K0572369, Mar 21 2008 |
| Number of levels: | 1, typical fasting glucose | 1, typical fasting glucose |
| Target ranges: | 94 – 140 mg/dL | 88 – 132 mg/dL |
| Analytes: | glucose | glucose |
| Container: | 6 mL LDPE vial with dispensing tipand cap | 6 mL LDPE vial with dispensing tipand cap |
| Fill volume: | 4 mL | 4 mL |
| Color: | red | red |
| Matrix: | Buffered, aqueous solution of D-Glucose, viscosity modifier,preservatives and other, non-reactive ingredients. | Buffered, aqueous solution of D-Glucose, viscosity modifier,preservatives and other, non-reactive ingredients. |
| Brands: | Infopia | Glucose Meter-Check |
1 This summary of safety and effectiveness is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
{1}------------------------------------------------
Description of the new device II.
Glucose Meter-Check Solution for Infopia is a buffered aqueous solution with glucose containing no ingredients of biological origin, or in concentrations qualifying as a controlled product under the Controlled Products Regulation. The Glucose Meter-Check Solution is formulated for optimal performance on Infopia glucose meters using Infopia test strips.
(a) (1) Intended use of the device
Glucose Meter-Check Solution for Infopia is intended for use to verify the performance and correct operation of Infopia blood glucose monitoring test systems utilizing the Element family of blood glucose test strips. Glucose Meter-Check Solution for Infopia is intended for use by healthcare professionals and people with diabetes mellitus at home.
Technological characteristics of the device. (a) (2)
This material consists of viscosity-adjusted, aqueous glucose control solution prepared with a single concentration of D-glucose with recovery on the test systems in the range corresponding to Interval 2 of the glucose contration intervals for evalution of intermediate precision in ISO 151972 (96 to 144 mg/dL). This solution has been optimized to simulate the response of whole blood on the blood glucose test systems manufactured by Infopia using Infopia blood glucose test strips. The solution contains no hazardous, human or animal derived components.
Summary of non-clinical tests submitted with the premarket notification for the device. (b) (1)
Tests were conducted to verify specific performance requirements:
- a) Closed bottle stability (Shelf-life)
- b) Stability after opening (Use-life)
- c) Transport Stability
- d) Test response
- Summary of clinical tests submitted with the premarket notification for the device. (b) (2) N/A
Conclusions drawn from the clinical and non-clinical trials. (b) (3)
Comparison of technological characteristics, formulation and intended use to predicate devices listed in this summary support the claim of substantial equivalence.
2 ISO 15197. In vitro diagnostic test systems – Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. 155 edition, May 2003.
{2}------------------------------------------------
TPLC Brand Name Detailed View
| Name | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | LANDLERS CREEN AR | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| THE COLORAL COLORIAL COLLECTION COLLEGION COLLEGION COLLEGION COLLEGION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CON | A production and annual a consideration and control and contractive de contractive de management de contrôleant de contrôleant de comments de combination of contrôleande de c | CARA A BALLERS A CONSULTION COLLEGION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONS | CARACA LEASING CARACT CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTIO | |||||||
| ------------------------------------------------------------------------------------------------ | Казанские продавания по представленные продавания пристемента на сединание пристемента пристементальным полнение можение можение можение можение можение можение можение можен |
Registration and Listing
Premarket Reviews Completed (None)
Under Review, Withdrawn or Closed without Product Code (1)
| K113764 | GLUCOSE METER-CHECK SOLUTION FOR INFOPIA | Review | Claudio Olga |
|---|---|---|---|
| Image | FDA.GOV JJK SINGLE ANALYTE CONTROL, ALL TYPES | K072369 | |
| K113764 | GLUCOSE METER-CHECK SOLUTION FOR INFOPIA | Review | Claudio Olga |
| Image | FDA.GOV JJK SINGLE ANALYTE CONTROL, ALL TYPES | K103021 |
MDR Summary (None)
MDR Analyst (None)
MDR Distribution by Brand - Death or Injury (None)
Patient Problems (None)
Patient Outcomes (None)
Device Problems (None)
Manufacturer Evaluation Results (None)
Manufacturer Evaluation Conclusions (None)
Recalls (None)
{3}------------------------------------------------
TPLC disclaimers
We are continuing to improve and enhance the TPLC Universe and the TPLC sheets. When more data is available we will update this message.
Please realize that in this initial release:
- -Recall data is only available since October, 2009.
- In the Premarket Under Review section and the Recall section, the premarket submission or recall is only included if the product code is specified in CTS.
- . The MDR count is a count of reports and contains duplicate reports.
- -MDR track action or additional information letters is not available yet.
- EIR data related to inspections is not yet displayed. -
- The TPLC name which consolidates variations on manufacturer names is not yet implemented.
- " Publications are not yet linked in.
We are working hard to address these issues and many can be addressed before the next release.
{4}------------------------------------------------
Image /page/4/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. In the center of the seal is a stylized representation of a caduceus, a symbol often associated with medicine and healthcare. The caduceus consists of a staff with two snakes coiled around it, topped by a pair of wings.
Food and Drug Administration
10903 New Hampshire Avenue Silver Spring, MD 20993
JAN 3 0 2012
Bionostics. Inc. c/o Randy Byrd Chief Technical Officer 7 Jackson Road Devens, MA 01434
Re: K113764 Glucose Meter-Check® Solution for Infopia Trade/Device Name: Regulation Number: 21 CFR 862.1660 Regulation Name: Quality Control Material Regulatory Class: Class I, reserved . Product Code: JJX Dated: December 20, 2011 Received: December 21, 2011
Dear Mr. Byrd:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may. therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
{5}------------------------------------------------
Page 2
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance ...
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm
Sincerely yours,
signature
Countney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{6}------------------------------------------------
Indications for Use
510(k) Number: Device Name: Indications for Use:
Glucose Meter-Check® Solution for Infopia Glucose Meter-Check Solution for Infopia is intended for use to verify the performance and correct operation of Infopia blood glucose monitoring test systems utilizing Infopia glucose test strips. Glucose Meter-Check Solution for Infopia is intended for use by healthcare professionals and people with diabetes mellitus at home.
For In Vitro Diagnostic Use
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrent of CDRH, Office of Device Evaluation (OIVD)
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K113764
Page 1 of 1
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.